BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 2019;14:e0216954. [PMID: 31086392 DOI: 10.1371/journal.pone.0216954] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
Number Citing Articles
1 Xing X, Zhao Q, Zhou J, Zhou R, Liu Y, Qin X, Zhang M, Zhong Y, Wang J, Tian M, Zhang H. Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging 2023. [PMID: 36622406 DOI: 10.1007/s00259-022-06084-1] [Reference Citation Analysis]
2 Spagnolo CC, Giuffrida G, Cannavò S, Franchina T, Silvestris N, Ruggeri RM, Santarpia M. Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. Cancers (Basel) 2022;15. [PMID: 36612243 DOI: 10.3390/cancers15010246] [Reference Citation Analysis]
3 Marie MA, McCallen JD, Hamedi ZS, Naqash AR, Hoffman A, Atwell D, Amara S, Muzaffar M, Walker PR, Yang LV. Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review. Front Oncol 2022;12:1023545. [PMID: 36568170 DOI: 10.3389/fonc.2022.1023545] [Reference Citation Analysis]
4 Wu L, Xu Y, Wang X, Cheng X, Zhang Y, Wang Y, Fan X, Zhao H, Liu H, Chai X, Zhang L, Wang M, Li N, Pan H, Lian X. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.. [DOI: 10.21203/rs.3.rs-2210602/v1] [Reference Citation Analysis]
5 Sun Q, Sun H, Wu N, Hu Y, Zhang F, Cong X. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. Front Oncol 2022;12:976224. [DOI: 10.3389/fonc.2022.976224] [Reference Citation Analysis]
6 Califaretti E, Dall’armellina S, Rovera G, Finessi M, Deandreis D. The role of PET/CT in thyroid autoimmune diseases. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03464-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
8 Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS. J Endocrinol Invest. [DOI: 10.1007/s40618-022-01845-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Glibka AA, Mazurina NV, Sarantseva KA, Kharkevich GY, Laktionov KK, Troshina EA, Mel`nichenko GA. Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors. Almanac of Clinical Medicine 2022. [DOI: 10.18786/2072-0505-2022-50-020] [Reference Citation Analysis]
10 Chen Y, Zhuang L, Zhang D, Du X, Sheng L, Cui D. Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma. Journal of Immunology Research 2022;2022:1-8. [DOI: 10.1155/2022/4015897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hu ZI, Link VM, Lima-Junior DS, Delaleu J, Bouladoux N, Han SJ, Collins N, Belkaid Y. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proc Natl Acad Sci U S A 2022;119:e2200348119. [PMID: 35727974 DOI: 10.1073/pnas.2200348119] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Labadzhyan A, Wentzel K, Hamid O, Chow K, Kim S, Piro L, Melmed S. Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study. J Clin Endocrinol Metab 2022;107:1976-82. [PMID: 35303106 DOI: 10.1210/clinem/dgac161] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, Wong A, Yang SP. Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers 2022;14:2687. [DOI: 10.3390/cancers14112687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Muir CA, Tsang VHM, Menzies AM, Clifton-bligh RJ. Immune Related Adverse Events of the Thyroid – A Narrative Review. Front Endocrinol 2022;13:886930. [DOI: 10.3389/fendo.2022.886930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Oki T, Inoue A, Nagatani Y, Oki M, Watanabe Y. Computed tomography imaging findings of nivolumab-induced thyroid dysfunction. JCIS 2022;12:22. [DOI: 10.25259/jcis_194_2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kotwal A, Mcleod DS. Thyroid Dysfunction from Treatments for Solid Organ Cancers. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, Varricchi G. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol 2022;13:804597. [PMID: 35432346 DOI: 10.3389/fimmu.2022.804597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Yao Y, Zhou X, Zhang A, Ma X, Zhu H, Yang Z, Li N. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring. European Journal of Radiology 2022;149:110200. [DOI: 10.1016/j.ejrad.2022.110200] [Reference Citation Analysis]
19 Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int 2022;71:169-78. [PMID: 35101349 DOI: 10.1016/j.alit.2022.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Paschou SA, Liontos M, Eleftherakis-papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos M. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Front Oncol 2022;12:847917. [DOI: 10.3389/fonc.2022.847917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Barnabei A, Corsello A, Paragliola RM, Iannantuono GM, Falzone L, Corsello SM, Torino F. Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle. Cancers (Basel) 2022;14:1057. [PMID: 35205804 DOI: 10.3390/cancers14041057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 George AS, Fernandez CJ, Eapen D, Pappachan JM. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. touchREV Endocrinol 2021;17:21-32. [PMID: 35118443 DOI: 10.17925/EE.2021.17.1.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Abdihamid O, Omar A, Rugambwa T. Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. Ecancermedicalscience 2021;15:1314. [PMID: 35047065 DOI: 10.3332/ecancer.2021.1314] [Reference Citation Analysis]
24 Cheung YM, Wang W, McGregor B, Hamnvik OR. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 2022. [PMID: 35022907 DOI: 10.1007/s00262-021-03128-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest 2021;:1-10. [PMID: 34658277 DOI: 10.1080/07357907.2021.1994586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Bardoscia L, Pasinetti N, Triggiani L, Cozzi S, Sardaro A. Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. Front Pharmacol 2021;12:746853. [PMID: 34790123 DOI: 10.3389/fphar.2021.746853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Kim BW. Overt Hyperthyroidism May Be a Good Prognostic Sign in Immune Checkpoint Inhibitor Treatment. Clinical Thyroidology 2021;33:467-9. [DOI: 10.1089/ct.2021;33.467-469] [Reference Citation Analysis]
28 Deligiorgi MV, Sagredou S, Vakkas L, Trafalis DT. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. Cancers (Basel) 2021;13:5277. [PMID: 34771441 DOI: 10.3390/cancers13215277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Chmielewska I, Dudzińska M, Szczyrek M, Świrska J, Wojas-Krawczyk K, Zwolak A. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? PLoS One 2021;16:e0257484. [PMID: 34587185 DOI: 10.1371/journal.pone.0257484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 2020;8:e000779. [PMID: 32606047 DOI: 10.1136/jitc-2020-000779] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
31 . September 30—October 3, 2021 Virtual. Thyroid 2021;31:A-1-A-114. [DOI: 10.1089/thy.2021.29115.abstracts] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
32 Matsui N, Kouda K, Ishihara N, Tamaki H, Yano T, Naora K, Kitahara T. Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. Jpn J Pharm Health Care Sci 2021;47:437-444. [DOI: 10.5649/jjphcs.47.437] [Reference Citation Analysis]
33 Kotwal A, Ryder M. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers. Curr Opin Endocrinol Diabetes Obes 2021;28:517-24. [PMID: 34269714 DOI: 10.1097/MED.0000000000000664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Jabkowski J, Loidl A, Auinger B, Kehrer H, Sepp N, Pichler R. Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report. Front Immunol 2021;12:606056. [PMID: 34220792 DOI: 10.3389/fimmu.2021.606056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Yamazaki N, Takenouchi T, Nakamura Y, Takahashi A, Namikawa K, Kitano S, Fujita T, Kubota K, Yamanaka T, Kawakami Y. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study). Jpn J Clin Oncol 2021;51:1232-41. [PMID: 34115870 DOI: 10.1093/jjco/hyab064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
36 Frelau A, Jali E, Campillo-Gimenez B, Pracht M, Porneuf M, Dinulescu M, Edeline J, Boussemart L, Lesimple T. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Res 2021;31:208-17. [PMID: 33904517 DOI: 10.1097/CMR.0000000000000739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Holstead RG, Kartolo BA, Hopman WM, Baetz TD. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Res 2021;31:258-63. [PMID: 33904518 DOI: 10.1097/CMR.0000000000000736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Street S, Chute D, Strohbehn I, Zhao S, Rengarajan M, Faje A, Seethapathy H, Lee M, Seethapathy R, Drobni Z, Rahma O, Neilan TG, Sullivan RJ, Villani AC, Zubiri L, Mooradian MJ, Reynolds KL, Sise ME. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann Oncol 2021;32:1050-1. [PMID: 34020034 DOI: 10.1016/j.annonc.2021.05.357] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
39 Russo L, Avesani G, Gui B, Trombadori CML, Salutari V, Perri MT, Di Paola V, Rodolfino E, Scambia G, Manfredi R. Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. Korean J Radiol 2021;22:1310-22. [PMID: 34047505 DOI: 10.3348/kjr.2020.1299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Iwama S, Kobayashi T, Arima H. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. Endocrinol Metab (Seoul) 2021;36:312-21. [PMID: 33934588 DOI: 10.3803/EnM.2021.1007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
41 Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 2021:dgab263. [PMID: 33878162 DOI: 10.1210/clinem/dgab263] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
42 Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Front Oncol 2021;11:633032. [PMID: 33912454 DOI: 10.3389/fonc.2021.633032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
43 Yoon JH, Hong AR, Kim HK, Kang HC. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors. Endocrinol Metab (Seoul) 2021;36:413-23. [PMID: 33820396 DOI: 10.3803/EnM.2020.906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol 2021;69:29-38. [PMID: 33640598 DOI: 10.1016/j.coi.2021.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
45 Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocr Pract 2021:S1530-891X(21)00030-6. [PMID: 33581327 DOI: 10.1016/j.eprac.2021.01.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Yamauchi I, Yasoda A, Hakata T, Yamashita T, Hirota K, Ueda Y, Fujii T, Taura D, Sone M, Inagaki N. Novel Thyroid-Specific Autoantibodies in Patients with Immune-Related Adverse Events Involving the Thyroid Gland.. [DOI: 10.1101/2021.01.14.426670] [Reference Citation Analysis]
47 Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother 2021;70:2023-33. [PMID: 33423089 DOI: 10.1007/s00262-020-02802-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
48 George AS, Fernandez CJ, Eapen D, Pappachan JM; Department of Medical Oncology, Lakeshore Hospital, Cochin, Kerala, India, Department of Endocrinology, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, UK, Department of Endocrinology, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, UK, Department of Endocrinology & Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston, UK, Manchester Metropolitan University, Manchester, UK, The University of Manchester, Manchester, UK. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology 2021;1:21. [DOI: 10.17925/ee.2021.1.1.21] [Reference Citation Analysis]
49 Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, Liu J, Ma X. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. Int Immunopharmacol 2021;91:107296. [PMID: 33360368 DOI: 10.1016/j.intimp.2020.107296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
50 Kroiß M, Schilling B, Deutschbein T. [Endocrine side effects of cancer immunotherapy]. Dtsch Med Wochenschr 2020;145:1736-41. [PMID: 33254246 DOI: 10.1055/a-1140-2920] [Reference Citation Analysis]
51 Yamauchi I, Taura D, Hakata T, Fujita H, Okamoto K, Ueda Y, Fujii T, Inagaki N. Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy. Clin Endocrinol (Oxf) 2021;94:258-68. [PMID: 33037658 DOI: 10.1111/cen.14349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol 2020;11:2023. [PMID: 33123120 DOI: 10.3389/fimmu.2020.02023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
53 Stelmachowska-Banaś M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect 2020;9:R207-28. [PMID: 33064663 DOI: 10.1530/EC-20-0342] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
54 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Frelau A, Palard-Novello X, Jali E, Boussemart L, Dupuy A, James P, Devillers A, Le Jeune F, Edeline J, Lesimple T, Girard A. Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunol Immunother 2021;70:679-87. [PMID: 32880684 DOI: 10.1007/s00262-020-02712-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Bisschop C, de Heer E, Brouwers A, Hospers G, Jalving M. Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. Critical Reviews in Oncology/Hematology 2020;153:103044. [DOI: 10.1016/j.critrevonc.2020.103044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
57 Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. Cancers (Basel) 2020;12:E2314. [PMID: 32824462 DOI: 10.3390/cancers12082314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
58 Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R, Perricone C, Gerli R. Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmun Rev 2020;19:102590. [PMID: 32561463 DOI: 10.1016/j.autrev.2020.102590] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
59 Shimozaki K, Sukawa Y, Beppu N, Kurihara I, Suzuki S, Mizuno R, Funakoshi T, Ikemura S, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Takaishi H, Kanai T. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. Cancer Manag Res 2020;12:4585-93. [PMID: 32606951 DOI: 10.2147/CMAR.S247554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
60 Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Maruyama K, Shakunaga N, Itakura E, Komoto A. Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance. J Dermatol 2020;47:834-48. [PMID: 32515086 DOI: 10.1111/1346-8138.15388] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
61 Frega S, Dal Maso A, Pasello G, Cuppari L, Bonanno L, Conte P, Evangelista L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers (Basel) 2020;12:E1303. [PMID: 32455666 DOI: 10.3390/cancers12051303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
62 Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid 2020;30:1458-69. [PMID: 32264785 DOI: 10.1089/thy.2020.0032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
63 Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020;18:87. [PMID: 32306958 DOI: 10.1186/s12916-020-01549-2] [Cited by in Crossref: 96] [Cited by in F6Publishing: 103] [Article Influence: 32.0] [Reference Citation Analysis]
64 Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, Yamashita S, Katsuda M, Hayata A, Akamatsu H, Jinnin M, Hara I, Yamaue H, Akamizu T. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci 2020;111:1468-77. [PMID: 32086984 DOI: 10.1111/cas.14363] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 14.7] [Reference Citation Analysis]
65 Kurihara S, Oikawa Y, Nakajima R, Satomura A, Tanaka R, Kagamu H, Shimada A. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report. J Diabetes Investig 2020;11:1006-9. [PMID: 31926048 DOI: 10.1111/jdi.13212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
66 Nivolumab. Reactions Weekly 2019;1757:236-236. [DOI: 10.1007/s40278-019-63464-6] [Reference Citation Analysis]